Agenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease
|
|
- Carol Johnson
- 5 years ago
- Views:
Transcription
1
2 Agenda Predictive markers in IBD Management of ulcerative colitis Management of Crohn s disease 2
3 Patients With UC (%) Distribution of UC Disease Severity at Presentation 1 Fulminant disease (9%) Moderate to higher activity (71%) N=1,161 2 Low activity (2%) Disease Activity Langholz EP et al. Scand J Gastroenterol. 1991;26:
4 Patients With UC (%) Course of UC 1 8 Disease Course One Year After Diagnosis Moderate-high activity (2%) 4 3 Colectomy Rate (%) 6 Low activity (3%) No symptoms (5%) 1 Disease activity Years Hendriksen C et al, Gut. 1985;26:
5 Predictors of Poor Response or Colectomy 1-5 Serum albumin ESR >3 mm/h Bandemia Prolonged flare Active infection Hospitalization setting 5 Severe endoscopic lesions 4 Stool frequency 1 Percentage of bloody stools 1 Body temperature >37.5 C 1,4 Heart rate >9 bpm 4 Increased CRP 1,2,4 Toxic megacolon Low hemoglobin <1.5 g/dl Disease duration 3 BPM=beats per minute; CRP=c-reactive protein; ESR=erythrocyte sedimentation rate. 1. Lindgren SC et al. Eur J Gastroenterol Hepatol. 1998;1: ; 2. Gonzalez-Lama Y et al. Hepatogastroenterology. 28;55: ; 3. Suzuki Y et al. Dig Dis Sci. 26;51: ; 4. Cacheux W et al. Am J Gastroenterol 28;13: Ananthakrishnan AN et al. Am J Gastroenterol. 28;13:
6 Impact of Mucosal Healing on Disease Course in UC 6
7 Mucosal Healing as a Surrogate for Longer-Term Outcomes Associated with: Better quality of life Fewer hospitalizations Fewer surgeries Longer time to clinical relapse Reduction in dysplasia/cancer Sands, B. ACG-FDA Workshop 212 7
8 Mucosal Healing: Added Value Beyond Clinical Remission? Support for biologic plausibility of clinical remission Increased specificity of clinical remission Surrogate marker for longer-term outcomes Sands, B. ACG-FDA Workshop 212 8
9 Proportion of UC patients not colectomised Impact of Mucosal Damage on Subsequent Resection in a Population Series: UC 1,,98,96 Patients without endoscopic activity at 1- year visit,94,92 Patients with endoscopic activity at 1-year visit, Time in years after 1 year visit Frøslie KF, et al. Gastroenterology. 27;133: Patients with compromised mucosa 1 year after diagnosis showed a trend toward more surgeries. 9
10 Mucosal Healing and Time to Colectomy in Infliximab-treated Patients P< Time to coloectomy infliximab use (weeks) = NORMAL endoscopy subscore = endoscopy subscore = 1 endoscopy subscore = 2 endoscopy subscore = 3 1 = MILD 2 = MODERATE 3 = SEVERE Colombel JF et al. Gastroenterology. 211;141:
11 Patients (%) The Majority of IBD Patients in Clinical Remission Have Mucosal Inflammation 5 Frequency of Mucosal Healing in Patients Without Clinical Symptoms n=47 n=51 n=47 n=51 n=51 No endoscopic inflammation + Endoscopic & histologic inflammation n=51 + Histologic inflammation 2 n=2 + Endoscopic inflammation Baars JE et al. Inflamm Bowel Dis. 212;18(9):
12 Poor Correlation Between Mucosal Healing and Clinical Remission With Infliximab in ACT 1 Trial Week 8 Week 3 Week 54 Patients (%) Patients (%) Patients (%) * 62 * 39 Mucosal healing Clinical remission * 5 * 34 Mucosal healing Clinical remission * 46 * 35 Mucosal healing Clinical remission Placebo (n=121) Infliximab 5mg (n=121) Placebo (n=121) Infliximab 5mg (n=121) Placebo (n=121) Infliximab 5mg (n=121) *P.1 vs placebo based on a two-sided Cochran-Mantel-Haenszel X 2 test Mucosal healing = Mayo score or 1 Rutgeerts et al. N Engl J Med. 25;353(23):
13 Interpreting Discordance of Clinical Remission and Mucosal Healing Mucosal Healing+ Mucosal Healing- Clinical Remission + True remission Clinical remission driven by placebo response? Clinical remission driven by pharmacologic effects other than direct effect on inflammation? Clinical Remission - Other conditions driving symptoms (e.g. IBS) Irreversible disease complications driving symptoms (e.g. fibrosis, lead pipe rectosigmoid) True lack of response Modified from Sands, B. ACG-FDA 212 Workshop 13
14 Histologic Inflammation Predicts Relapse in UC Patients with relapse (%) 1 Acute inflammatory cell infiltrate (N=27) Patients with relapse (%) 1 Crypt abscesses (N=27) 52% P=.2 78% P<.5 25% 27% Infiltrate No infiltrate Patients with Mucin depletion (N=27) relapse (%) 1 P<.2 56% Patients with relapse (%) 1 Presence 75% Absence Breaches in surface epithelium (N=27) P=.1 26% 31% Depletion Riley SA et al. Gut. 1991;32: Presence Presence Absence 14
15 Surrogates for Mucosal Healing in UC (Endoscopy is Not an Ideal Surrogate Measure) Candidates include: CRP, fecal leukocyte markers CRP: Clinically useful, nonparametric distribution, large variances, nonproduction Calprotectin, fecal lactoferrin: Differential expression by disease and anatomical location, role in predicting relapse Modified from Feagan, B. ACG-FDA Workshop,
16 % of Patients Use of Fecal Calprotectin as Marker of Disease Activity in Patients Taking Maintenance Infliximab for UC # of Patients N=113 UC patients on infliximab 5 mg/kg in stable remission with 5 mg/kg infliximab q8w. Fecal calprotectin (FC) measured monthly for 1 year Deep remission (DR) = normal endoscopy at baseline and week 52 + Mayo score < 3 Active disease = clinical Mayo score or endoscopic score 2 at week year outcome /113 3/113 28/113 Remission DR Discontinued FC levels highly correlate with disease activity in pts on IFX maintenance therapy for UC. DR is associated with very low levels of FC. A flare is associated with high levels (median >3 mg/kg). Two consecutive levels of >3 mg/kg predict a flare. Median FC < 5 mg/kg at all measured time points Reason for D/C 5 16 Flare Safety Withdrew consent Median FC 477 mg/kg. Increase in FC observed already 3 months prior. Two consecutive FC measurements >3 mg/kg predicted flare De Vos M et al. Presented at ECCO 212; February 16-18, 212; Barcelona, Spain. Abstract OP7. 16
17 Mucosal Healing in UC Mucosal healing (by whatever criteria) is associated with improved outcomes (histologic>endoscopic>clinical) No validated definitions of: Endoscopic/histologic healing Significant intra/inter-observer variations No validated surrogates Practicality of achieving mucosal healing (by whatever criteria) in clinical trials/clinical practice Is almost as good as complete? 17
18 Sequential Therapies for UC Disease Severity at Presentation Severe Anti-TNF Cyclosporine Colectomy Anti-TNF Thiopurine Moderate Corticosteroid Aminosalicylate Thiopurine Mild Aminosalicylate Aminosalicylate Induction Maintenance Therapy is stepped up according to severity at presentation or failure at prior step 18
19 Summary of UC Therapies Mesalamine (oral ± topical) induction and maintenance for mild-moderate disease Corticosteroid induction for moderate-severe disease Thiopurines maintain steroid-induced remission Anti-TNF agents for steroid-refractory induction or steroid-dependent maintenance (± thiopurine) 19
20 Clinical Predictors for Disabling Crohn s Disease Age of onset [below 4 years of age] (P=.4) Small bowel disease location (P=.2) Perianal lesions at diagnosis (P=.1) Need for steroids at first flare (P=.1) Current smoker (P=.9) P values reflect non-disabling vs. disabling CD Beaugerie L et al. Gastroenterology. 26;13:
21 Patients (%) Points D Haens Study: Mucosal Healing Improved With Top-down Strategy Mucosal Healing * 88 # 1 8 Early combined immunosuppression (n=24) Conventional management (n=2) # 2.15 Complete Ulcer Healing 1 Reduction 2 Endoscopic healing was scored in 5 ileal and colonic segments as follows: =no ulcers, 1= aphthoid ulcers, 2=larger ulcers, 3= ulcerated stenosis. * P=.28; # P<.1 1. D Haens G et al. Lancet. 28;371: D Haens GR et al. Gastroenterology. 26;13:A-11. Abstract 764. Reduction in Endoscopic Score 1 21
22 Serum Markers for IBD Marker Prevalence ASCA (or other anti-glycans) 35% 76% of CD patients 1,2 Anti-CBir1 5% 55% of CD patients 3 Anti-OmpC 55% of CD patients 4 Anti-I2 54% of CD patients 5 IBD-specific (DNase) panca 1% 25% of CD patients 4% 6% of UC patients panca 3% 83% of UC patients 1 1. Sandborn WJ. Rev Gastroenterol Disord. 24;4: ; 2. Dotan I et al. Gastroenterology, 26:131: ; 3. Targan SR et al. Gastroenterology. 25;128:22-228; 4. Landers CJ et al. Gastroenterology. 22;123: ; 5. Sutton CL et al. Gastroenterology. 2;119:23-31; 22
23 Risk of Disease Progression Increases With Increased Serum Immune Responses CLINICAL PHENOTYPE NUMBER OF ANTIBODIES TOWARD MICROBIAL ANTIGENS* P trend ODDS RATIO (3 vs ) 95% CI (3 vs ) Fibrostenosing (%) < Internal perforating (%) < Small bowel surgery (%) < *Percentage of patients with a specific disease phenotype; antigens include: I2, OmpC (outer membrane porin C), and ASCA (anti-saccharomyces cerevisiae). Results are irrespective of panca and NOD/CARD15 status. Mow S et al. Gastroenterology. 24;126:
24 Probability of non-progressive CD Prediction of Internal-Penetrating / Stricturing Disease: Quantitative Assessment With Antibody Sum Survival estimates according to antibody sum 1 ab_sum=1 ab_sum=.75 ab_sum=3 ab_sum= P< Time to IP/S Behavior (mo) Markers assessed included ASCA (anti-saccharomyces cerevisiae), OmpC (outer membrane protein complex), CBir1 (flagellin). CD = Crohn s disease; IP/S = internal-penetrating/stricturing Dubinsky M et al. Clin Gastroenterol Hepatol. 28;6:
25 Sensitivity (True positive) Receiver-Operator Curves for Individual Markers Marginal Discrimination: IBD vs. non-ibd Test AUC ANCA ELISA.685 ASCA-IgA.734 ASCA-IgG.723 CBir1.641 OmpC.7 No Discrimination Specificty (False positive) Plevy SE, et al. Presented at DDW; May 19, 212. San Diego, CA. Abstract
26 Sensitivity (True positive) 1. ROC Curve for Combined Serology Testing Test AUC IBD S7.843 ANCA ELISA.685 ASCA-IgA.734 ASCA-IgG.723 CBir1.641 OmpC.7 No Discrimination Specificty (False positive) Plevy SE, et al. Presented at DDW; May 19, 212. San Diego, CA. Abstract
27 In contrast to clinical remission in Crohn s disease, maintenance of endoscopic remission does influence longterm course 27
28 % of Patients in Remission Mucosal Healing Predicts Sustained Clinical Remission in Early CD Simple endoscopic score at year 2 Simple endoscopic score 1-9 at year Remission on Steroids Off Steroids and No Anti-TNF During Years During Years Baert FJ et al. Gastroenterology. 21;138:
29 Rate of Hospitalizations and Surgeries (%) Infliximab: Endoscopic Healing and Reduced Hospitalizations and/or Surgeries Hospitalization Surgery Patients with no healing (n=74) Patients with healing at 1 visit (1 or 54 weeks) (n=16) Patients with healing at both visits (1 and 54 weeks) (n=9) Rutgeerts P et al. Gastroenterology. July 22;123(1) Suppl:43. Abstract no. M
30 EXTEND: Patients Who Achieved Deep Remission * with Adalimumab at Week 12 and Hospitalization Rates All hospitalization (%) CD-related hospitalization (%) All-cause hospitalization through Week 52 CD-related hospitalization through Week /11 9/53 Deep remission * (Week 12) Non-deep remission * (Week 12) /11 5/53 Deep remission * (Week 12) Non-deep remission * (Week 12) * Deep remission defined as clinical remission (CDAI <15) and complete mucosal healing in EXTEND CDAI=Crohn s disease activity index Colombel JF et al. Gut. 21;59(Suppl 3):A8. 3
31 Impact of Biologic-induced Deep Remission 31
32 Discontinuation of Infliximab in Patients in Stable Remission on Combination Therapy (Azathioprine Maintained) ±4% 79±4% ±5% 56±5% 5±5% 5±5%.2 52 relapses in 115 patients Median (±SE) follow up 21 ± 1 mo 52 relapses in 115 patients Median (±SE) follow up 21 1 mo Months Since Inclusion # at risk : Louis E et al. Gastroenterology. 212;142:
33 Multivariate Analysis of Factors Predicting Time-to-Relapse: Factor HR (95%CI) P Male 3.7( ) <.1 No surgery 4. ( ).1 Steroid treat. (month -12 to -6) 3.5 ( ).3 Hemoglobin 14.5 (g/dl) 6. ( ) <.1 WBC > 6 (1 9 /L) 2.4 ( ).1 CRP hs 5 (mg/l) 3.2 ( ) <.1 CDEIS > 2.3 ( ).4 CDEIS=Crohn s disease endoscopic index of severity. Louis E et al. Gastroenterology. 212;142:
34 Predictive Model for Time-to-Relapse Kaplan Meier time-to-relapse curves according to multivariate models and scores generated through Cox model using multiple imputations method Deleterious factors: No previous surgery Steroids within 12-6 months before infliximab withdrawal Male gender Hemoglobin 14.5 g/dl, Leukocyte count >6x1 9 /L, hscrp 5 mg/l, Fecal calprotectin 3 µg/g, CDEIS>, infliximab trough 2 mg/l Louis E et al. Gastroenterology. 212;142: Proportion Without Relapse Months since infliximab withdrawal No. deleterious factors < >6 34
35 Concept Deep remission (clinical, biologic, endoscopic) is associated with improved outcomes However, maintenance therapy is still required Analogous to postoperative remission 35
36 Patients (%) Prevention of Endoscopic Recurrence in Postoperative Crohn s Disease: Infliximab 9 Infliximab (N = 11) Placebo (N = 13) Infliximab vs placebo P= /11 11/13 Recurrence Endoscopic Recurrence defined as endoscopic scores of i2, i3, or i4. Regueiro M et al. Gastroenterology. 29;136:
37 % of Patients in Remission Mucosal Healing Predicts Sustained (2-year) Clinical Remission in Early CD Simple endoscopic score at year 2 Simple endoscopic score 1-9 at year Remission on Steroids Off Steroids and No Anti-TNF During Years During Years Baert FJ et al. Gastroenterology. 21;138:
38 Cumulative Probability (%) Impact of Therapy Depends on Degree of Structural Damage and Velocity of Progression 1 9 High Potential Low Potential Penetrating Inflammatory Stricturing 12 Patients at risk: Months N = Cosnes J et al. Inflamm Bowel Dis. 22;8(4):
39 Remission (%) CHARM: Remission by Disease Duration With Adalimumab at Week 26 Placebo All adalimumab P=.8 46 P= P< <2 years n=23, n=39 <2-5 years n= 36, n=57 5 years n=111, n=233 Schreiber S et al. Journal of Crohn s and Colitis (212), doi: 1.116/j.crohns
40 Patients in Deep Remission* at Week 52 (%) EXTEND: Disease Duration and Deep Remission* Rates Placebo Adalimumab 4 mg eow /9 3/9 /15 2/11 /41 7/44 2 years >2 to 5 years Disease Duration >5 years *Deep remission defined as clinical remission (CDAI <15) and complete mucosal healing in EXTEND P<.1 for adalimumab vs placebo, adjusted for baseline disease duration (Cochran-Mantel-Haenszel test) All patients (n=135) received adalimumab 16/8 mg induction therapy, before randomization (n=129) to adalimumab 4mg eow or to placebo CDAI=Crohn s disease activity index; eow=every other week. Colombel J et al. Inflamm Bowel Dis. 211;17:S44. Abstract P
41 % in CDAI Response or Remission n=19 n=35 n=19 n=35 n=2 n=22 n=2 n=22 n=45 n=55 n=45 n=55 n=131 n=98 n=131 n=98 Response and Remission to Certolizumab Pegol in Crohn s Disease vs Disease Duration 1 9 9% % 68% 37% 75% 5% 55% 36% 62% 36% 47% 29% 57% 33% 44% 24% 1 Data from the PRECiSE 2 study <1 Year 1 to <2 years 2 to <5 years 5 years Response Placebo Response Remission Placebo Remission Schreiber S. et al. Am J Gastroenterol. 21;15:
42 Sequential Therapies for Crohn s Disease Disease Severity at Presentation Severe Anti-TNF Natalizumab Anti-TNF+/- Thiopurine/MTX Moderate Corticosteroid Thiopurine/MTX Mild Aminosalicylate Budesonide Aminosalicylate Budesonide/Thiopurine Induction Maintenance Step-up according to severity at presentation or failure at prior step 42
43 Disease activity Accelerated Step-Care Therapy with Early Azathioprine (e-aza) Versus Conventional Step- Care Therapy in CD: A Randomized Study Percent Aim: To compare accelerated stepcare strategy with early AZA (IMS) versus conventional step-care therapy in patients with early CD and predictors of disabling disease (age at diagnosis <4, steroid use at first flare, perianal disease) N=71 Accelerated Step-Care (e-aza) e-aza 142 patients N=71 Conventional Therapy Primary Endpoint Controls IMS + Anti-TNF IMS + Anti-TNF 4 2 IMS + Corticosteroids Corticosteroids Conventional Therapy IMS + Corticosteroids Accelerated Step-Care AZA=azathioprine; IMS=immunosuppressor; TNF=tumor necrosis factor Cosnes J, et al. Presented at DDW; May 22, 212. Abstract 943c. Total Early AZA use in patients at high risk for disabling disease has no significant impact on the subsequent 3-year CD course. Conventional therapy could allow physicians to vaccinate patients before immunomodulator therapy. 43
44 Evolving Goals of Therapy for IBD: Sustained Deep Remission Goal Response Clinical Parameters Improved symptoms Outcomes Improved QoL Remission No symptoms Normal labs Decreased hospitalisation Deep remission Normal endoscopy Mucosal healing Avoidance of surgery Minimal/no disability SUSTAINED QoL=quality of life Modified from Panaccione R. Presented at: European Crohn s and Colitis Organization (ECCO) Fifth Annual Congress. Prague, Czech Republic; February 21 44
45 Maintenance with Biologics can be Optimized by Pharmacology and Determination of Trough Levels 45
46 Percent of patients (%) Corticosteroid-Free Clinical Remission at Week 5 1 Patients with CRP.8 mg/dl and Lesions on Baseline Endoscopy* P=.2 8 P=.16 P= /75 27/65 32/64 AZA+ placebo IFX + placebo IFX + AZA * Patients who did not enter the study extension were treated as nonresponders AZA=azathioprine; IFX=infliximab Colombel JF et al. N Engl J Med. 21;362:
47 Proportion of Patients (%) Steroid-Free Clinical Remission at Week 26 by Antibody to Infliximab Status at Week /185 12/18 9/16 Inconclusive Negative Positive ATI=AZA=azathioprine; IFX=infliximab Colombel JF et al. N Engl J Med. 21;362:
48 Median serum IFX concentration* at Week 3 (mcg/ml) Median Serum Infliximab Levels at Week P< IFX + Placebo (n=97) IFX + AZA (n=19) * IFX + placebo- or IFX/AZA-treated patients who had serum samples collected prior to infusion at Week 3 (N=26) AZA=azathioprine; IFX=infliximab Colombel JF et al. N Engl J Med. 21;362:
49 Steroid-free Clinical Remission at Week 26 by Median Trough IFX Concentration at Week 3 (SONIC) Proportion of Patients (%) /32 13/23 43/59 36/49 31/43 >-1 >1-3 >3-6 >6 IFX + placebo or IFX/AZA-treated patients who had serum samples collected prior to infusion at Week 3 (N=26) IFX=infliximab Colombel JF et al. N Engl J Med. 21;362:
50 Infliximab Trough Levels and CRP During Infliximab-Immunomodulator Combination Treatment Objective To study the influence of immunomodulator withdrawal on infliximab trough levels and to identify predictors of disease flare and loss of response to infliximab after withdrawal of immunomodulators Patients (N=223) On infliximab maintenance therapy for CD, of whom 155 were cotreated with immunomodulators Treatments Immunomodulators discontinued in 117 patients when durable clinical remission was achieved after >6 months of cotreatment Drobne D et al. Gastroenterology. 211;14(5, Suppl 1):S-62. Abstract
51 No loss of response Loss of Response After Immunomodulator Withdrawal 1 Stop of Infliximab Due to Loss of Response after Immunomodulator Withdrawal 8 6 TL detectable & CRP <5 mg/l TL detectable & CRP >5 mg/l TL undetectable & CRP >5 mg/l Months TL=trough levels Drobne D et al. Gastroenterology. 211;14(5, Suppl 1):S-62. Abstract
52 Conclusions Undetectable infliximab trough levels and CRP >5 mg/l during combination therapy are associated with an increased loss of response to infliximab after immunomodulator withdrawal Drobne D et al. Gastroenterology. 211;14(5, Suppl 1):S-62. Abstract
53 Maintenance of Biologic Trough Levels High dose-induction followed by maintenance therapy Combination therapy to reduce immunogenicity 1 Avoid drug holidays 1 Monitor trough levels 1 to avoid Biologic relapse Development of immunogenicity Ordas I et al. Clin Gastroenterol Hepatol, (1):
54 Summary Personalized management for IBD depends on: Disease severity at presentation Clinical and biologic prognostic factors Achievement of clinical and biologic remission Maintenance of clinical and biologic remission Patient adherence Therapeutic monitoring 54
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University
More information5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD
5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationAssociation Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean Frédéric Colombel, William J. Sandborn, Matthieu Allez, Jean Louis Dupas, Olivier
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationJoin the conversation at #GIFORUMCCFA
1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationDisease behavior in adult patients- are there predictors for stricture or fistula formation?
Disease behavior in adult patients- are there predictors for stricture or fistula formation? Falk Symposium 168, Madrid, Spain Iris Dotan, M.D., Head, IBD Center, Department of Gastroenterology and Liver
More informationSelby Inflamm Bowel Dis. 2008:14:
Medical Management of Inflammatory Bowel Disease Freddy Caldera D.O. Assistant Professor Division of Gastroenterology Objectives Discuss Crohn s disease and Ulcerative Colitis Discuss Medications for Inflammatory
More informationImplementation of disease and safety predictors during disease management in UC
Implementation of disease and safety predictors during disease management in UC DR ARIELLA SHITRIT DIGESTIVE DISEASES INSTITUTE SHAARE ZEDEK MEDICAL CENTER JERUSALEM Case presentation A 52 year old male
More informationTreating to Achieve a Target and Disease Monitoring in 2015: State of the Art
Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art David T. Rubin, MD The Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationAchieving Success in Ulcerative Colitis: the Role of Infliximab
Achieving Success in Ulcerative Colitis: the Role of Infliximab Dr Gill Watermeyer IBD clinic Groote Schuur Hospital 17 th August 2012 Inflammatory Bowel Disease Crohn s disease and ulcerative colitis
More informationCrohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?
Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation? Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationWithdrawal of drug therapy in patients with quiescent Crohn s disease
Withdrawal of drug therapy in patients with quiescent Crohn s disease DR. JEAN-FRÉDÉRIC COLOMBEL DIRECTOR OF THE IBD CENTER, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, USA Withdrawal of drug therapy
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationEmerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationStrategies for changing the course of Crohn s disease
Strategies for changing the course of Crohn s disease Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Where we are now and where we want to be Diagnosis (usually endoscopy)
More informationSevere IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
More informationCROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM
CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM Crohn's Disease Ulcerative Colitis Steroids x 2 No prior AZA/6-MP Biologic Agent AZA/6-MP STEP-UP MANAGEMENT APPROACH Advantages Patients attain remission
More informationPredicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab.
Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab. Dr Peter Irving Guy s and St Thomas Hospital, London King s College London Response to vedolizumab
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationNew Perspectives on the Diagnosis and Management of IBD. Disclosures
New Perspectives on the Diagnosis and Management of IBD Joel R. Rosh, MD Director, Pediatric Gastroenterology Goryeb Children's Hospital/Atlantic Health Professor of Pediatrics Icahn School of Medicine
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationINFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL
INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL A. Hillary Steinhart, MD MSc FRCP(C) Medical Lead, Mount Sinai Hospital IBD Centre Professor of Medicine University
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my
More informationImmunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
More informationAnti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis
Anti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis University, 1st Department of Medicine Budapest June 13-15,
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationEmerging Therapies in IBD 2006
Overview Emerging Therapies in IBD 26 David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Describe the unmet needs of therapy in IBD Emerging biologic
More informationOptimal Use of Immunomodulators and Biologics
3/17/214 Optimal Use of Immunomodulators and Biologics Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota, U.S.A. Loftus Disclosures
More informationBest Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease
Mark Lazarev, MD November 14, 2013 Assistant Professor of Medicine, Johns Hopkins University School of Medicine Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease 1 Talk outline
More informationHow to use infliximab?
How to use infliximab? Séverine Vermeire, MD, PhD Division of Gastroenterology University Hospital Gasthuisberg Leuven The how to use infliximab rules Before starting IFX: try optimizing chances for response!
More informationPerianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
More informationUlcerative Colitis: Refining our Management and Incorporating Newer Concepts
Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz The Mt. Sinai School of Medicine Refining our Management
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationPredicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium
Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight
More informationFibrotic complications of inflammatory bowel disease
January 27th 2017, 8th Gastro Foundation Weekend for Fellows; Spier Hotel & Conference Centre, Stellenbosch Fibrotic complications of inflammatory bowel disease Gerhard Rogler, Department of Gastroenterology
More informationLatest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D.
Latest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D. Co-Director, IBD Center Director, Nutrition Support Service UPMC Presbyterian Hospital Division of Gastroenterology,
More informationCAG Symposium: Management of IBD in 2018
CAG Symposium: Management of IBD in 2018 Waqqas Afif, MD, M. Sc., FRCPC, Associate Professor, Department of Medicine Division of Gastroenterology McGill University Health Center X X X X X CanMEDS Roles
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More information4/16/2018. Updates in Crohn s Disease. Disclosures. Learning Objectives. Crohn s Disease is Progressive and Destructive
4/16/218 Disclosures Updates in Crohn s Disease David T. Rubin, MD Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition University of Chicago Consultant
More informationThe Refractory Crohn s Disease
The Refractory Crohn s Disease Patient David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationMedical Management of Intestinal Strictures
Medical Management of Intestinal Strictures Subrata Ghosh, FRCP, FRCPE, FRCPC, AGAF, FCAHS Professor of Translational Medicine Director of the Institute of Translational Medicine University of Birmingham,
More information2nd Nottingham IBD Masterclass, 2017
2nd Nottingham IBD Masterclass, 217 Positioning IL12/IL23 blockade in the Crohn s disease treatment algorithm Prof James Lindsay, Consultant Gastroenterologist, Barts Health NHS Trust Professor in Inflammatory
More informationThe future of IBD therapeutic research
The future of IBD therapeutic research Jean-Frederic Colombel, MD Director Susan and Leonard Feinstein IBD Clinical Center Icahn School of Medicine, Mount Sinai Hospital New York J-F Colombel has served
More informationWhich is the Safest Strategy to Treat Moderate to Severe IBD?
Which is the Safest Strategy to Treat Moderate to Severe IBD? David G. Binion, M.D. Co-Director, Inflammatory Bowel Disease Center Director, Translational Inflammatory Bowel Disease Research Visiting Professor
More informationUlcerative Colitis: State of the Art 2006
Ulcerative Colitis: State of the Art David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Improving Management of Ulcerative Colitis (UC) Better classification/diagnostic
More informationOptimizing Therapies for Severe Ulcerative Colitis October 19, 2014
Optimizing Therapies for Severe Ulcerative Colitis October 19, 2014 Ellen J. Scherl, MD, FACP, FACG, AGAF, FASGE, NYSGEF Director Jill Roberts Center for Inflammatory Bowel Disease Jill Roberts IBD Research
More informationIl ruolo degli anticorpi anti farmaco nella pratica clinica
Il ruolo degli anticorpi anti farmaco nella pratica clinica Daniela Pugliese, MD IBD Unit Complesso Integrato Columbus Gemelli Hospital Catholic University Foundation, Rome - Italy Therapeutic Drug monitoring
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationΑπό τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων
Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Conflict of interest By means of this, the speaker confirms that
More informationTherapy for Inflammatory Bowel Disease
Therapy for Inflammatory Bowel Disease Jonathan P. Terdiman, MD Professor of Clinical Medicine Clinical Director, Center for Colitis and Crohn s Disease University of California San Francisco, CA UC: Current
More informationIBD Tools to Aid in the Accurate Diagnosis of Inflammatory Bowel Disease
IBD Tools to Aid in the Accurate Diagnosis of Inflammatory Bowel Disease Inflammatory Bowel Disease Experts in Autoimmunity Inova Diagnostics offers a complete array of methods to aid in the diagnosis
More informationDrug Level Monitoring in IBD. Objectives
Drug Level Monitoring in IBD Corey A. Siegel, MD, MS Director, Dartmouth-Hitchcock IBD Center Associate Professor of Medicine, Geisel School of Medicine at Dartmouth Objectives Review non-biologic drug
More informationNew and Future Adhesion Molecule Based Therapies in IBD
New and Future Adhesion Molecule Based Therapies in IBD Brian G. Feagan Professor of Medicine, Epidemiology and Biostatistics University of Western Ontario Robarts Clinical Trials London, Ontario, Canada
More informationCrohn s Disease: The First Visit
Crohn s Disease: The First Visit Jack A. Di Palma, MD University of South Alabama Mobile, Alabama 1 Adverse Experiences Colombel, SONIC N Engl J Med 2010 Any Adverse Event Serious Adverse Event Azathioprine
More informationOptimizing Management using CRP, Fecal Calprotectin and Ferritin. Peter Laszlo Lakatos 1st Department of Medicine Semmelweis University Budapest
Optimizing Management using CRP, Fecal Calprotectin and Ferritin Peter Laszlo Lakatos 1st Department of Medicine Semmelweis University Budapest Objectives Overview of disease progression Old and new treatment
More informationCLINICAL INSIGHTS 01
P2 Borrowing a Treatment Paradigm From Rheumatoid Arthritis P4 Antidrug Antibody Monitoring in Practice P6 Proactive Drug Monitoring Informs Therapeutic Dose Adjustments P7 Keeping Patients in Remission
More informationBiologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA
Biologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA Overview Indications and Drug Selection Contraindications
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationPersonalized Medicine: IBD
Use of Anti-TNF Antibodies and Other Serologies for Managing IBD Christopher J. Shepela, MD, MS Assistant Professor of Medicine University of Minnesota Medical Director at Digestive Disease Center at Regions
More informationBiologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases
Biologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases Walter Reinisch Univ-Klinik für Innere Medizin III Abt. Gastroenterologie & Hepatologie AKH Wien The Biologic s evolution From availabilitydriven
More informationTitle: Author: Journal:
IMPORTANT COPYRIGHT NOTICE: This electronic article is provided to you by courtesy of Ferring Pharmaceuticals. The document is provided for personal usage only. Further reproduction and/or distribution
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationBest Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease
Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease Mark Lazarev, MD Summary Inflammatory bowel disease (IBD) is a complex disease that is costly both in terms of medical costs
More informationClinical Study Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis
Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2013, Article ID 192794, 6 pages http://dx.doi.org/10.1155/2013/192794 Clinical Study Clinical Study of the Relation between
More informationUlcerative colitis (UC) is a chronic inflammatory
Induction and Maintenance Therapy with Vedolizumab, a Novel Biologic Therapy for Ulcerative Colitis Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance
More informationEvolving Inflammatory Bowel Disease Treatment Paradigms: Top-Down Versus Step-Up
Evolving Inflammatory Bowel Disease Treatment Paradigms: Top-Down Versus Step-Up Shane M. Devlin, MD, Remo Panaccione, MD* KEYWORDS Inflammatory bowel disease Crohn disease Ulcerative colitis Management
More informationCOPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease
Inflammatory Bowel Disease What Every Clinician Needs to Know Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard
More informationDr David Epstein Vincent Pallotti Hospital and University of Cape Town
Inflammatory Bowel Disease Management in South Africa in 2016 Pharmaceutical Care Management Association Dr David Epstein Vincent Pallotti Hospital and University of Cape Town Inflammatory Bowel Disease
More informationPercent Cumulative. Probability. Penetrating. Inflammatory. Stricturing. Months Patients at risk N =
Fistulizing Crohn s Disease Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology & Hepatology Mayo Clinic Rochester, Minnesota, USA Outline Fistulizing Crohn s Etiology Incidence
More information